FDA nixes 'one-size-fits-all' biosimilars process; Valeant posts big hike in profits;

@FiercePharma: Dendreon cites CMS review for sales trouble, but The Street's take is more plausible: Cash-flow-conscious oncologists. Article | Follow @FiercePharma

> FDA officials say regulatory approval for biosimilars can't depend on a "one-size-fits-all" process, but on an approach specific to each product. Report

> Valeant Pharmaceutical profits skyrocketed by 66% on strong sales in Europe, Latin America, Canada and Australia. Article

> Generics maker Par Pharmaceutical beat analyst estimates for second-quarter profits, but revenue dropped by 12% to $224.2 million. News

> Mexico's Instituto Bioclon won the FDA nod for Anascorp, the first-ever treatment designed specifically for scorpion stings. FDA release | News

> As Medco Health Solutions stock drops on worries that U.S. antitrust regulators will block the Express Scripts buyout, arbitragers are jumping into the gap. Item

Biotech News

@FierceBiotech: Celgene tackles anemia in $242M development pact with Acceleron. Piece | Follow @FierceBiotech

@JohnCFierce: Bloomberg covers the provenge disaster. Doctors confused about coverage? Really? I'm not buying it. Item | Follow @JohnCFierce

@MaureenFierce: FDA's Woodcock on biosimilars: No "one size fits all" approach. Report | Follow @MaureenFierce

> Tiny French biotech touts success of new hep C vaccine. More

> FDA sketches a complex instruction manual for biosimilars. Story

> Pfizer axes $195M Biotica pact, hands back rights to MS, lupus drugs. Item 

> Tiny trial suffices for FDA approval of scorpion sting antidote. Report 

Manufacturing News

> Musty odor exudes from J&J board report exonerating execs. More

> Pharma slices cargo theft in H1 2011. Report

> FDA foreign force multiplier demo'd in API inspections. Article

> Catalent catches the cold chain wave. News

> Developed world feeling sting of fake drugs. Story

Vaccines News

> FDA delays decision on Pfizer's Prevnar 13. News

> Inviragen forms dengue partnership with IVI. More

> Start-up Vaxxas lands $16.46M for vaccine nanopatch. Article

> Merck, Serum Institute sign pneumococcal vaccine deal. Report

And Finally... SSRI antidepressants may carry more side effects than tricyclics in people over 65. Story

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…